Hoth Therapeutics Inc.
News
Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial
PR Newswire Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial PR Newswire NEW YORK, Sept. 5, 2024...\n more…
Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001
PR Newswire Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001 Hoth Therapeutics Announces Positive Data from...\n more…
Short Interest in Hoth Therapeutics, Inc. (NASDAQ:HOTH) Declines By 39.8%
Ticker Report Hoth Therapeutics, Inc. (NASDAQ:HOTH - Get Free Report) was the target of a significant decline in short interest during the month of August. As of August 15th, there was short interest totalling...\n more…
Hoth Therapeutics (NASDAQ:HOTH) Stock Rating Upgraded by EF Hutton Acquisition Co. I
Ticker Report Hoth Therapeutics (NASDAQ:HOTH - Get Free Report) was upgraded by investment analysts at EF Hutton Acquisition Co. I to a "strong-buy" rating in a report released on Wednesday, Zacks.com reports...\n more…
Hoth Therapeutics, Inc. (NASDAQ:HOTH) CEO Acquires $16,750.00 in Stock
Ticker Report Hoth Therapeutics, Inc. (NASDAQ:HOTH - Get Free Report) CEO Robb Knie acquired 25,000 shares of Hoth Therapeutics stock in a transaction dated Friday, August 16th. The stock was purchased at an...\n more…